Medical cannabis in 2026: what 2,500+ studies actually show about benefits, risks, and the Schedule III question

A sweeping JAMA review examined over 2,500 cannabis-related scientific papers published between 2010 and 2025 and reached a conclusion that may surprise both advocates and opponents: "While many people turn to cannabis seeking relief, our review highlights significant gaps between public perception and scientific evidence regarding its effectiveness for most medical conditions." A separate 2026 Lancet Psychiatry analysis of 50+ randomized controlled trials found limited high-quality evidence for cannabis treating mental health conditions. This guide walks through every major condition, ranks the evidence honestly, explains the rescheduling situation as of March 2026, and helps you have an informed conversation with your doctor.

The Schedule III rescheduling situation (March 2026)

There is significant confusion about the current legal status. Here's the timeline and reality:

August 2023: HHS recommended to DEA that marijuana be moved from Schedule I to Schedule III, concluding it has "currently accepted medical use" and lower abuse potential.

May 2024: DOJ issued a proposed rule to reschedule. Hearings were requested by multiple parties.

January 2025: The DEA administrative law judge postponed the scheduled hearing due to an appeal.

December 18, 2025: President Trump signed an executive order directing the Attorney General to "take all necessary steps to complete rescheduling in the most expeditious manner."

January 6, 2026: DEA publicly clarified that the rescheduling process "remains pending" and must still proceed through required administrative steps.

February 2026: Trump signed legislation preventing Washington D.C. from legalizing marijuana. AG Bondi reversed Biden-era possession amnesty and directed federal prosecution for personal possession.

What this means in plain English: The executive order expressed intent, but did not change marijuana's legal status. As of March 2026, marijuana remains Schedule I federally. The rescheduling process could produce a final rule in 2026, but experts describe this as uncertain. Legal experts note a contradiction between the executive order supporting rescheduling and the DOJ's simultaneous pursuit of possession charges. Cannabis policy analysts describe the situation as the administration supporting rescheduling "in words" while pursuing prohibition "in actions."

What Schedule III would (and wouldn't) change: Moving to Schedule III would formally recognize cannabis's medical value, reduce research barriers, and eliminate the Section 280E tax burden on cannabis businesses. It would NOT legalize recreational marijuana, allow state dispensaries to operate under federal law, or create a system where doctors can simply "prescribe" cannabis from dispensaries. FDA-approved drugs (Epidiolex, Marinol, Syndros) would be the only cannabis products legally prescribable under Schedule III.

Medical conditions ranked by evidence strength

Below is our evidence-ranked assessment of every major condition for which cannabis is commonly used or studied. These ratings reflect the consensus of the JAMA 2025 review, the Lancet Psychiatry 2026 analysis, and our own cross-referencing of individual RCTs. "Evidence" here means high-quality randomized controlled trials in humans — not animal studies, not anecdotes, not survey data.

Tier 1: Strong evidence (8-9/10)

Epilepsy (specifically Dravet and Lennox-Gastaut syndromes) — 9.0/10

This is cannabis medicine's clearest success story. Epidiolex (purified CBD) is FDA-approved for seizure reduction in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. Multiple large-scale RCTs demonstrated significant seizure reduction versus placebo. This is the only FDA-approved plant-derived cannabis medicine and represents the gold standard for evidence in this space.

Chemotherapy-induced nausea and vomiting — 8.5/10

THC-based medicines (Marinol/dronabinol and Syndros) are FDA-approved for chemotherapy nausea. This was one of the earliest medical applications of cannabinoids and has decades of clinical evidence. Nabilone (Cesamet), a synthetic THC analog, is also approved for this indication. The evidence here is well-established.

Chronic pain — 8.0/10

Chronic pain is the most common reason patients seek medical cannabis. The evidence base is substantial: multiple systematic reviews support modest but meaningful pain reduction with cannabis, particularly for neuropathic pain. A clinical trial found that a balanced THC:CBD treatment reduced chronic temporomandibular disorder pain significantly, with functional pain dropping approximately 90%. However, the JAMA review notes that effect sizes are typically moderate, cannabis is not superior to all existing treatments, and long-term safety data remains limited. The evidence is strongest for neuropathic pain, moderate for inflammatory pain, and weakest for acute pain. For non-cannabis approaches to pain and inflammation, see our guides on omega-3 (anti-inflammatory) and curcumin (NF-kB inhibition).

Multiple sclerosis spasticity — 8.0/10

Sativex (nabiximols — a 1:1 THC:CBD oromucosal spray) is approved in 25+ countries (not the US) for MS-related spasticity. Clinical trials demonstrate meaningful spasticity reduction. This is one of the most well-characterized therapeutic applications of full-spectrum cannabis medicine.

Tier 2: Moderate or emerging evidence (6-7.5/10)

Insomnia — 7.0/10

A 2026 clinical trial found that a cannabis-based herbal formula performed similarly to lorazepam (a benzodiazepine) for chronic insomnia, with additional benefits for sleep quality. CBD+THC combinations appear most effective for sleep, with CBD alone less effective than combinations. However, high-dose THC may disrupt REM sleep architecture with chronic use, potentially reducing sleep quality over time despite faster sleep onset. For non-cannabis sleep protocols with strong evidence and no REM disruption, see our Sleep Stack guide (magnesium, L-theanine, apigenin, glycine) and best sleep supplements.

Anxiety (acute, CBD-specific) — 6.5/10

This is where the nuance matters enormously. The Lancet Psychiatry 2026 review found that "cannabinoids as a whole haven't been shown to be helpful for anxiety." But researchers note that picture changes when you look at specific compounds — CBD specifically has shown promise in several trials for acute anxiety reduction. THC, by contrast, can worsen anxiety at higher doses. For non-cannabis anxiety support, ashwagandha (KSM-66) has stronger evidence for chronic anxiety/stress reduction at lower cost and with a clearer safety profile.

Autism spectrum disorder (emerging) — 6.0/10

CBDV (cannabidivarin) is being studied in multiple ongoing trials for reducing irritability and behavioral problems in children with ASD. Early results are promising but not yet definitive.

Tier 3: Weak or insufficient evidence (4-5.5/10)

Depression — 5.0/10

The Lancet Psychiatry review found no significant evidence that cannabis effectively treats depression in controlled trials. For evidence-based mood support, our Mood Stack covers ashwagandha, rhodiola, saffron, and omega-3 — all with stronger controlled-trial evidence for mood improvement.

PTSD — 5.0/10

Despite PTSD being one of the most common qualifying conditions for medical cannabis in state programs, the controlled-trial evidence is limited. VA-funded trials are ongoing but have not yet produced definitive results.

ADHD — 4.5/10

Very limited controlled evidence. Some patients report symptom improvement, but a 2026 systematic review found no compelling RCT data supporting cannabis for ADHD.

THC:CBD ratios: the pharmacology that actually matters

Cannabis's effects depend enormously on the ratio of THC to CBD. The same plant can be therapeutic or harmful depending on this ratio.

Safety: what the research says about risks

Cardiovascular risk

The JAMA review recommends that clinicians screen for cardiovascular disease before recommending THC-containing products. THC temporarily increases heart rate and may affect blood pressure.

Psychosis and mental health risk

A 2025 review of nearly 100 studies found strong links between high-potency cannabis (high-THC products) and psychosis, schizophrenia, and cannabis use disorder. The risk increases with potency, frequency of use, and younger age of onset. CBD may be protective against psychosis.

Cognitive effects

Regular THC use is associated with impairments in working memory, attention, and processing speed, particularly with adolescent onset. These effects are at least partially reversible with abstinence. For evidence-based cognitive enhancement without these risks, see our Cognitive Stack and Lion's Mane guide.

Drug interactions

Both THC and CBD inhibit CYP450 enzymes. CBD in particular is a potent inhibitor of CYP2C19 and CYP3A4. This interaction concern is shared with several herbal supplements — berberine and curcumin with BioPerine similarly affect CYP enzymes.

Cannabis use disorder

Approximately 9% of people who use cannabis develop cannabis use disorder (rising to 17% among those who start in adolescence).

FDA-approved cannabinoid medicines

Cannabis vs. Health Britannica supplement alternatives by condition

How to talk to your doctor about medical cannabis

Be specific about your condition and what you've tried. "I have chronic neuropathic pain that hasn't responded to X and Y" is far more useful than "I want a medical marijuana card."

Ask about THC:CBD ratios. For anxiety and inflammation, CBD-dominant products (<=1:6 ratio) have better safety profiles. For pain, balanced ratios may be more effective but carry more side effects.

Disclose all medications and supplements. Cannabis interacts with many common drugs through CYP450 inhibition. This includes supplements like berberine and curcumin with BioPerine.

Start low, go slow. Begin with the lowest available dose and increase gradually under medical supervision.

Track your outcomes. Keep a simple log of dose, timing, symptom relief, and side effects.

Bottom line

Medical cannabis is neither the miracle cure its advocates claim nor the menace its opponents fear. The evidence is genuinely strong for a handful of conditions — epilepsy (Epidiolex is FDA-approved), chemotherapy nausea (Marinol has decades of data), neuropathic pain (multiple systematic reviews), and MS spasticity (Sativex is approved in 25+ countries). For these conditions, cannabinoid medicines represent real therapeutic options.

For the conditions that drive most consumer interest — anxiety, depression, sleep, general wellness — the evidence is notably weaker. For these conditions, the Mood Stack, Sleep Stack, and evidence-based herbal alternatives like ashwagandha, saffron, and Lion's Mane often have equal or stronger controlled-trial evidence with fewer side effects.

The rescheduling situation remains uncertain. Whatever happens legislatively, the science will continue to clarify which patients benefit most from which cannabinoid compounds at which ratios. Health Britannica will continue to cover this research honestly — including the findings that don't match the narrative on either side.